Cargando…

P985: THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF

Detalles Bibliográficos
Autores principales:	Coltro, G., Rotunno, G., Mannelli, F., Loscocco, G. G., Bartalucci, N., Mannarelli, C., Maccari, C., Guglielmelli, P., Vannucchi, A. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430524/ http://dx.doi.org/10.1097/01.HS9.0000846808.30540.ef

Ejemplares similares

ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
por: Guglielmelli, Paola, et al.
Publicado: (2022)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2023)

Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis
por: Mannelli, Francesco, et al.
Publicado: (2022)

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients
por: Ruberti, S, et al.
Publicado: (2018)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
por: Loscocco, Giuseppe G., et al.
Publicado: (2022)

Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
por: Vannucchi, A M, et al.
Publicado: (2014)

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
por: Pacilli, Annalisa, et al.
Publicado: (2018)

Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data
por: Loscocco, Giuseppe G, et al.
Publicado: (2020)

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

PMF: the front end electronic of the ALFA detector
por: Barrillon, P, et al.
Publicado: (2010)

PMF: the front end electronic of the ALFA detector
por: Barrillon, P, et al.
Publicado: (2008)

Validation of the Mayo alliance prognostic system for mastocytosis
por: Mannelli, Francesco, et al.
Publicado: (2019)

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2020)

Reliable Time Propagation Algorithms for PMF and RBPMF
por: Sung, Chang-Ky, et al.
Publicado: (2021)

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
por: Guglielmelli, P, et al.
Publicado: (2015)

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera
por: Carobbio, Alessandra, et al.
Publicado: (2022)

Myeloid sarcoma: more and less than a distinct entity
por: Loscocco, Giuseppe G., et al.
Publicado: (2023)

Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms
por: Tenedini, E, et al.
Publicado: (2014)

P985: CLL-1 IS AN ADOPTIVE IMMUNOTHERAPY TARGET IN JUVENILE MYELOMONOCYTIC LEUKEMIA
por: Huebner, Juwita, et al.
Publicado: (2023)

Characterization of the Partitioning System of Myxococcus Plasmid pMF1
por: Sun, Xia, et al.
Publicado: (2011)

Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells
por: Guglielmelli, Paola, et al.
Publicado: (2015)

Mutations and thrombosis in essential thrombocythemia
por: Guglielmelli, Paola, et al.
Publicado: (2021)

A deep catalog of protein-coding variation in 985,830 individuals
por: Sun, Kathie Y., et al.
Publicado: (2023)

985. Impact of Age and Medical Comorbidities on Renal Outcomes in the DISCOVER Trial
por: Daar, Eric, et al.
Publicado: (2020)

Comprehensive biomarker profiling of hypertension in 36 985 Finnish individuals
por: Palmu, Joonatan, et al.
Publicado: (2022)

Clinical and genetic profiles of 985 Chinese families with skeletal dysplasia
por: Li, Shanshan, et al.
Publicado: (2023)

PLB-985 Neutrophil-Like Cells as a Model To Study Aspergillus fumigatus Pathogenesis
por: Rafiq, Muhammad, et al.
Publicado: (2022)

Cementless bipolar hemiarthroplasty in a patient with PMF: a case report
por: Alturki, Abdullah A, et al.
Publicado: (2019)

985. Pooled RNA Metagenomics to Enable Scalable, Unbiased Pathogen Detection and Surveillance
por: Messer, Katelyn S, et al.
Publicado: (2023)

Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
por: Bartalucci, Niccolò, et al.
Publicado: (2013)

mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
por: Bogani, Costanza, et al.
Publicado: (2013)

Characteristics of 985 pediatric burn patients in the south of Liaoning province of China
por: Zhai, Hongjun, et al.
Publicado: (2014)

Membrane Dynamics and Organization of the Phagocyte NADPH Oxidase in PLB-985 Cells
por: Joly, Jérémy, et al.
Publicado: (2020)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
por: Ayoub, Maya C., et al.
Publicado: (2023)

Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon.
por: Double, J. A., et al.
Publicado: (1986)

Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real‐life setting: An Italian MYNERVA Project
por: Coltro, Giacomo, et al.
Publicado: (2023)

985. Safety of Guidelines Recommending LAIV for Routine Use in Children and Adolescents With Asthma
por: Nordin, James, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pq9q5piqdssr7b5q8pmpp69h85